A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN)
Latest Information Update: 21 May 2025
At a glance
- Drugs Ianalumab (Primary)
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms SIRIUS-LN
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 02 Jun 2023 According to a Lupus Therapeutics Media Release, the company announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.The company will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.
- 21 Jul 2022 Planned End Date changed from 3 Apr 2031 to 15 Jul 2030.
- 21 Jul 2022 Planned primary completion date changed from 5 Oct 2029 to 1 Mar 2027.